Market Overview

The global Pneumonia Vaccine market was valued at USD 10.23 billion in 2022 and expected to grow at a CAGR of 6.7% during the forecast period. Pneumonia vaccines are vaccines designed to prevent or reduce the severity of pneumococcal disease, which is caused by the bacterium Streptococcus pneumoniae. Pneumonia can cause a range of symptoms, including fever, cough, chest pain, difficulty breathing, and fatigue, and can lead to serious complications such as sepsis and meningitis. Pneumonia vaccines are recommended for people who are at increased risk of developing pneumococcal disease, including: Infants and young children, Adults over 65 years of age, Individuals with weakened immune systems, such as those with HIV/AIDS, cancer, or organ transplants, Individuals with chronic medical conditions such as diabetes, heart disease, or lung disease

There are two main types of pneumonia vaccines:

Pneumococcal conjugate vaccine (PCV): This vaccine is recommended for infants and young children, as well as for adults with certain medical conditions. It protects against 13 strains of pneumococcal bacteria.

Pneumococcal polysaccharide vaccine (PPV): This vaccine is recommended for adults over 65 years of age, as well as for individuals with certain medical conditions. It protects against 23 strains of pneumococcal bacteria.

Both vaccines are generally safe and effective, although some people may experience mild side effects such as redness or swelling at the injection site, fever, or muscle aches. It's important to note that while the pneumonia vaccines can reduce the risk of pneumococcal disease, they do not protect against all strains of the bacteria that can cause pneumonia. Therefore, it's important to practice good hygiene, such as washing your hands regularly and avoiding close contact with sick people, to help reduce your risk of developing pneumococcal disease.

The global pneumonia vaccine market is a rapidly growing industry that is expected to continue to expand in the coming years. This growth is being driven by several factors, including an aging population, rising prevalence of pneumococcal disease, increasing awareness of the importance of vaccination, and government initiatives aimed at improving vaccination rates.

The market is primarily dominated by a few key players, including Pfizer, Merck & Co., Inc., and GlaxoSmithKline plc. These companies have a strong presence in the market and are investing in research and development to improve existing vaccines and develop new ones.

The market is segmented by type of vaccine, target population, and geography. Pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPV) are the two main types of vaccines, with PPV being the larger segment in terms of revenue. The market is also segmented by target population, with adults and the elderly being the largest segment in terms of revenue.

Geographically, North America is the largest market for pneumonia vaccines, followed by Europe and Asia-Pacific. The high prevalence of pneumococcal disease in North America and Europe, along with high vaccination rates and government support for vaccination programs, are driving growth in these regions. The Asia-Pacific market is expected to grow rapidly in the coming years due to increasing awareness of vaccination and government initiatives to improve vaccination rates.

Overall, the global pneumonia vaccine market is expected to continue to grow at a steady pace in the coming years due to the increasing prevalence of pneumococcal disease and rising awareness of the importance of vaccination. The market is expected to remain dominated by a few key players, with new entrants facing significant regulatory and clinical challenges in developing and bringing new vaccines to market.

Report Scope

Impact of COVID

The COVID-19 pandemic has had a significant impact on the pneumonia vaccine market. While the pandemic has brought increased attention to the importance of vaccination, it has also disrupted the supply chain and distribution of vaccines, leading to delays and shortages in some regions.

In addition, the focus of healthcare systems and governments around the world has been largely on the development and distribution of COVID-19 vaccines, which has resulted in decreased attention and resources being given to other vaccines, including pneumonia vaccines. This has led to a decline in demand for pneumonia vaccines in some regions, as well as delays in clinical trials and research on new vaccine candidates.

However, the pandemic has also highlighted the importance of protecting vulnerable populations, such as the elderly and those with weakened immune systems, from infectious diseases such as pneumonia. This has led to increased emphasis on vaccination campaigns targeting these populations, which is expected to drive demand for pneumonia vaccines in the coming years.

Furthermore, the COVID-19 pandemic has led to an increased focus on respiratory illnesses and their impact on public health, which may lead to greater awareness and investment in pneumonia vaccines in the future. Overall, while the COVID-19 pandemic has had a short-term impact on the pneumonia vaccine market, it is expected that demand for pneumonia vaccines will continue to grow in the long term due to increasing awareness of the importance of vaccination and the need to protect vulnerable populations.

Vaccine Type Insights

the global pneumonia vaccine market is primarily dominated by the pneumococcal polysaccharide vaccines (PPV) segment, which holds the largest share of the market in terms of revenue. The PPV segment is expected to maintain its dominant position in the market over the forecast period due to its effectiveness in preventing pneumococcal infections in adults.

However, the pneumococcal conjugate vaccines (PCV) segment is also expected to grow rapidly in the coming years, driven by increasing vaccination rates in children and adults with certain medical conditions. The PCV segment is expected to grow at a higher CAGR than the PPV segment due to the higher effectiveness of the PCV vaccines in preventing pneumococcal infections in children.

In terms of market share, the major players in the pneumonia vaccine market include Pfizer, Merck & Co., Inc., and GlaxoSmithKline plc, who hold a significant share of both the PPV and PCV segments. Other key players in the market include Sanofi Pasteur, Serum Institute of India, and Bharat Biotech International Limited.

Geographically, North America is the largest market for pneumonia vaccines, followed by Europe and the Asia-Pacific region. The high prevalence of pneumococcal disease and high vaccination rates in North America and Europe are the major factors driving growth in these regions, while the Asia-Pacific market is expected to grow rapidly in the coming years due to increasing awareness of vaccination and government initiatives to improve vaccination rates.

Product Type Insights

Prevnar 13 holds the largest share of the pneumonia vaccine market in terms of revenue. This vaccine is a pneumococcal conjugate vaccine (PCV) developed by Pfizer and is primarily used to protect against pneumococcal infections in children and adults. Prevnar 13 is highly effective in preventing invasive pneumococcal disease caused by the 13 serotypes included in the vaccine.

Synflorix is another PCV developed by GlaxoSmithKline, which holds the second-largest market share in terms of revenue. This vaccine is also primarily used to protect against pneumococcal infections in children and is highly effective in preventing invasive pneumococcal disease caused by the 10 serotypes included in the vaccine.

Pneumovax23, developed by Merck & Co., Inc., is a pneumococcal polysaccharide vaccine (PPV) used to protect against pneumococcal infections in adults. It contains 23 different pneumococcal polysaccharides and is highly effective in preventing invasive pneumococcal disease in adults.

Geographically, North America and Europe are the largest markets for all three products, while the Asia-Pacific market is expected to grow rapidly in the coming years. The major players in the pneumonia vaccine market, including Pfizer, Merck & Co., Inc., and GlaxoSmithKline plc, hold a significant share of all three product segments. Other key players in the market include Sanofi Pasteur, Serum Institute of India, and Bharat Biotech International Limited.

Regional Insights

North America holds the largest share of the pneumonia vaccine market, primarily due to the high prevalence of pneumococcal disease and high vaccination rates in the region. The United States is the largest market in the region, driven by high healthcare expenditure, high awareness about vaccination, and well-established healthcare infrastructure.

Europe is the second-largest market for pneumonia vaccines, driven by high vaccination rates and government initiatives to improve vaccination coverage. Countries such as Germany, France, and the United Kingdom are major markets in the region.

The Asia-Pacific region is expected to grow rapidly in the coming years, driven by increasing awareness of vaccination, rising healthcare expenditure, and government initiatives to improve vaccination rates. China and India are expected to be the largest markets in the region, due to their large populations and high burden of pneumococcal disease.

Latin America and Middle East & Africa are also expected to grow significantly in the coming years, driven by improving healthcare infrastructure and increasing awareness of vaccination. However, the market in these regions is still relatively small compared to North America, Europe, and the Asia-Pacific region.

The major players in the pneumonia vaccine market, including Pfizer, Merck & Co., Inc., and GlaxoSmithKline plc, have a significant presence in all regions and hold a large share of the market. Other key players in the market, such as Sanofi Pasteur, Serum Institute of India, and Bharat Biotech International Limited, also have a significant presence in multiple regions.

Competitive Analysis

Some of the major companies operating within the market are Glaxosmithkline plc, LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Bioscience, and Walvax Biotechnology Co., Ltd. These players are focusing on product innovation, expansion, and partnerships to strengthen their market position and meet the growing demand for Pneumonia Vaccine globally.

Recent News

·         In September 2020, in September 2020, Shinogi inked a partnership deal with HanaVax to jointly focus into the commercialization, R&D, manufacturing, and distribution of the Streptococcus pneumonia vaccine range developed by the latter.

Why to buy this Report?

The report provides quantitative and qualitative aspect for the market in terms of value and volume, along with supporting market trends, challenges, restraints.

The report provides an in depth analysis from both production and consumption point of view at the regional and country level. Key Factors considered within the report scope are Production capacity by countries/regions, average price, consumption ratio, revenue earned and gross margin.

The report provides competitive analysis of around 30-50 companies operated in the market, these companies are bifurcated into niche players, the leaders and major contenders. The companies are analyzed in terms of following factors such as:

§  Business Model

§  Production Capacity, Revenue, Sales, Gross Margin

§  Key Business Strategy

§  SWOT Analysis

In terms of competitive landscape, the report provides distinctive factors that would help the end user in taking a key decision within the business:

§  Company Share Analysis from 2018-2022

§  Company Analysis by Revenue and Sales

§  Company Production Capacity, Gross Margin

§  Company Share Analysis by Application/End Use

§  Company Share Analysis by Product/Specification

Frequently Asked Questions

·         What is the market size and growth projections?

·         What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?

·         What are the top performing segments, and countries / regions of each of the markets?

·         What is the market size and growth rate across key countries / regions?

·         How big is the global & regional market in terms of revenue and volume?

·         How far market will grow in forecast period in terms of revenue and volume?

·         What factors will influence demand and supply trends across each markets during the forecast period?

·         What are the technology trends shaping various markets?

·         Which country / region has more opportunities?

·         What is the COVID-19 impact on the market and how long will it take to recover?

·         Who are the key competitors of market Players?

·         What are the market share (%) of Key Players?

·         What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?

·         What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?